TNG348 is a novel USP1 (ubiquitin-specific protease 1) inhibitor for the treatment of BRCA1/2-mutant and other homologous recombination deficiency (HRD)+ cancers. HRD+ cancers, including BRCA1/2 mutations, represent up to 50% of ovarian cancers, 25% of breast cancers, 10% of prostate cancers and 5% of pancreatic cancers. Tango is developing TNG348 from the preclinical USP1 program licensed from
In the study, TNG348 will be evaluated both as single agent and in combination with olaparib (PARP-inhibitor). in patients with BRCA1/2-mutant and other HRD+ cancers. Preclinical data has shown synergistic effect with PARP inhibitors in PARP naïve models, including models with resistance to PARP inhibitors.
- "The preclinical data generated by Tango for TNG348 is promising and dosing the first patient in a clinical study is encouraging for patients with HRD+ cancers. The efforts undertaken by Tango to develop TNG348 into a clinical-staged drug are impressive and we will continue to follow the clinical development of TNG348 with great anticipation", says
Under the licensing agreement,
For additional information, please contact;
Telephone: +46 8 5468 3100.
E-mail: magnus.christensen@medivir.com
About
https://news.cision.com/medivir/r/medivir-s-licensee--tango-therapeutics--has-dosed-the-first-patient-with-tng348--a-novel-usp1-inhibi,c3904079
https://mb.cision.com/Main/652/3904079/2522650.pdf
(c) 2024 Cision. All rights reserved., source